NASDAQ:FMI Foundation Medicine (FMI) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free FMI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$137.00▼$137.0050-Day Range N/A52-Week Range$31.70▼$137.20VolumeN/AAverage Volume621,352 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Foundation Medicine alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Foundation Medicine Stock (NASDAQ:FMI)Foundation Medicine, Inc. provides various molecular information products in the United States. The company's molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic insights about each patient's individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted therapies and immunotherapies. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood-based cancers, or hematologic malignancies, including leukemia, lymphoma, and sarcomas; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer; and FoundationOne CDx, a diagnostic assay for solid tumors. The company also offers FoundationCORE, a knowledgebase to publish scientific and medical advances, and foster relationships throughout the oncology community. In addition, it has strategic collaboration agreements with F. Hoffmann-La Roche Ltd.; and Genentech, Inc. Foundation Medicine, Inc. has a collaboration with The European Organisation for Research and Treatment of Cancer to advance precision medicine using comprehensive genomic profiling to facilitate clinical trial enrollment. It also has a three-party collaboration agreement with F. Hoffmann-La Roche Ltd and DIAN Diagnostics Group, Co., Ltd. to integrate the company's comprehensive genomic profiling assays into clinical patient care in mainland China. The company was founded in 2009 and is headquartered in Cambridge, Massachusetts. Foundation Medicine, Inc. is a subsidiary of Roche Holdings, Inc.Read More Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. FMI Stock News HeadlinesApril 24, 2024 | finanznachrichten.deF. Hoffmann-La Roche Ltd: Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19April 15, 2024 | msn.comINTO University Partnerships’ Foundation Medicine program enjoys huge successApril 25, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 19, 2024 | msn.comFoundation Medicine consolidates employees in new Seaport headquartersMarch 6, 2024 | tmcnet.comFoundation Medicine Announces Details of Presentations at the 2024 American Association for Cancer Research (AACR) Annual MeetingFebruary 28, 2024 | time.comMedicine: It WorksFebruary 27, 2024 | msn.comPrisma Health Midlands Foundation begins $2 million campaign for new and improved diabetic facilitiesFebruary 22, 2024 | msn.comArgentine austerity anger mounts, but govt says its workingApril 25, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 20, 2024 | forbes.comSupermarkets Lead On Food And Nutrition Initiatives, Study SuggestsFebruary 19, 2024 | forbes.comSupermarkets At Center Of Food As Medicine According To New StudyJanuary 25, 2024 | businesswire.comCystic Fibrosis Foundation Funds Up to $15 Million to Prime Medicine to Pursue Gene Editing in CFJanuary 19, 2024 | msn.comCompanies You Didnt Know Were Military ContractorsJanuary 18, 2024 | msn.comThe Largest US Military Contractors in Every StateJanuary 11, 2024 | bizjournals.comWinter Park Health Foundation CEO to retireJanuary 8, 2024 | msn.comGroup practice opening in former South Bend Medical Foundation buildingDecember 14, 2023 | bizjournals.comLongtime Roche executive to lead subsidiary Foundation MedicineDecember 14, 2023 | finance.yahoo.comFoundation Medicine Appoints Dan Malarek as Chief Executive OfficerDecember 14, 2023 | businesswire.comAnHeart Therapeutics and Foundation Medicine Announce Collaboration to Develop Tissue-Based and Liquid-Based Companion Diagnostics for Taletrectinib, a ROS1 InhibitorNovember 18, 2023 | businesswire.comFoundation Medicine Announces Participation in National Cancer Institute’s ComboMATCH Initiative to Connect Patients with New Anti-Cancer Drug CombinationsNovember 15, 2023 | finance.yahoo.comFoundation Medicine Announces Collaboration with Pierre Fabre Laboratories to Develop Companion Diagnostics in Non-Small Cell Lung CancerOctober 21, 2023 | businesswire.comFoundation Medicine Expands Partnership with Sequanta to Provide both Liquid and Tissue Genomic Profiling Services in China to Support Global Regulatory FilingsOctober 20, 2023 | businesswire.comNew Research from Foundation Medicine and Roche Demonstrates Improved Outcomes Following Treatment Based on Comprehensive Genomic Profiling in Patients with Cancer of Unknown ...October 19, 2023 | businesswire.comFoundation Medicine Announces Acceptance of 11 Abstracts at the 2023 European Society for Medical Oncology (ESMO) Annual MeetingAugust 24, 2023 | finance.yahoo.comWhole Exome Sequencing Global Market Report 2023August 23, 2023 | msn.comThe WHO Under Fire for Promoting ‘Pseudoscientific’ MedicineAugust 15, 2023 | msn.comPenn Medicine residents and fellows want a union, citing grueling workloads and 80-hour workweeksSee More Headlines Receive FMI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Foundation Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/02/2018Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:FMI CUSIPN/A CIK1488613 Webwww.foundationmedicine.com Phone617-418-2200FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable BetaN/A Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Troy Cox (Age 54)CEO, Pres & Director Mr. Michael Doherty (Age 59)Head of Product Devel. Mr. Jason Ryan (Age 44)Chief Financial Officer Mr. Konstantin Fiedler (Age 52)Chief Operating Officer Mr. Tom GoddenChief Information OfficerKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All Competitors FMI Stock Analysis - Frequently Asked Questions How were Foundation Medicine's earnings last quarter? Foundation Medicine, Inc. (NASDAQ:FMI) announced its quarterly earnings results on Wednesday, May, 2nd. The company reported ($1.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.10) by $0.08. The business earned $52.84 million during the quarter, compared to analysts' expectations of $44.99 million. The firm's revenue for the quarter was up 100.7% on a year-over-year basis. During the same period last year, the company earned ($1.31) EPS. What other stocks do shareholders of Foundation Medicine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Foundation Medicine investors own include Corbus Pharmaceuticals (CRBP), Visa (V), Gilead Sciences (GILD), HP (HPQ), Inovio Pharmaceuticals (INO), Viveve Medical (VIVE), Exact Sciences (EXAS), GW Pharmaceuticals (GWPH), NVIDIA (NVDA) and QUALCOMM (QCOM). This page (NASDAQ:FMI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyYour Money is Not SafeAmerican AlternativeThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foundation Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
